AzTrials
AzTrials

Psoriatic ArthritisPhase 3OPAL BROADENNCT01877668

Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study

A Phase 3 study testing Tofacitinib 5 mg BID, Tofacitinib 10 mg BID and Adalimumab in people with Psoriatic Arthritis, run by Pfizer at 123 sites in 16 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This is a 12-month study investigating the effectiveness and safety of tofactinib in treating the signs and symptoms of active psoriatic arthritis and improving physical function and preserving bone structure in patients with an inadequate response to a traditional, nonbiologic disease-modifying antirheumatic drug. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Psoriatic Arthritis
What is being tested?
Tofacitinib 5 mg BID, Tofacitinib 10 mg BID and Adalimumab
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
422 participants
Where
123 sitesin 16 countries
Study dates
20 Jan 2014to 18 Dec 2015
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Males or females, aged >= 18 years at time of consent.
  • Have a diagnosis of Psoriatic arthritis (PsA) of >= 6 months
  • Meet the Classification Criteria of PsA (CASPAR) at time of screening
  • Must not have been adequately treated with a a traditional non-biologic disease modifying anti-rheumatic drug (DMARD).
  • Concurrent treatment with methotrexate, leflunomide, or sulfasalazine allowed and required
  • Must not have taken a biologic Tumour Necrosis Factor Inhibitor
  • Must have 3 or more swollen joints AND 3 or more tender joints
  • Must have active psoriasis skin lesions

Who cannot join

  • Have non-plaque forms of psoriasis, eg erythrodermic, guttate or pustular, with the exception of nail psoriasis which is allowed
  • Pregnant or breast feeding, females of child-bearing potential not using highly effective contraception
  • New York Heart Association Class III and IV congestive heart failure
  • History of hypersensitivity or infusion reaction to biologic agents
  • Infection with HIV, hepatitis B virus, hepatitis C virus, or other chronic infection

Trial locations and contacts

123 sites in 16 countries.

123 sites in 16 countries

United States24 sites
  • Rheumatology Associates, PC

    Birmingham, Alabama, 35205

  • Low Country Rheumatology, PA

    Charleston, South Carolina, 29406

  • Medvin Clinical Research

    Covina, California, 91723

  • Altoona Center for Clinical Research

    Duncansville, Pennsylvania, 16635

  • St. Paul Rheumatology, PA

    Eagan, Minnesota, 55121

  • Arizona Arthritis & Rheumatology Associates, P.C.

    Glendale, Arizona, 85306

  • Klein & Associates, M.D., P.A.

    Hagerstown, Maryland, 21740

  • Pioneer Research Solutions, Inc.

    Houston, Texas, 77008

  • Rheumatology Associates of North Alabama, PC

    Huntsville, Alabama, 35801

  • Dartmouth-Hitchcock Medical Center (DHMC)

    Lebanon, New Hampshire, 03756

  • Physician Research Collaboration, LLC

    Lincoln, Nebraska, 68516

  • Paramount Medical Research & Consulting, LLC

    Middleburg Heights, Ohio, 44130

  • Millennium Research

    Ormond Beach, Florida, 32174

  • Desert Medical Advances

    Palm Desert, California, 92260

  • Arthritis Center, Inc.

    Palm Harbor, Florida, 34684

  • Advances In Medicine (X-Rays)

    Rancho Mirage, California, 92270

  • Drug Shipment/Storage: Huntsman Cancer Hospital at the University of Utah

    Salt Lake City, Utah, 84112

  • University of Utah Hospital & Clinics

    Salt Lake City, Utah, 84132

  • San Diego Arthritis Medical Clinic

    San Diego, California, 92108

  • Dynacare Laboratories (Specimen processing for shipment)

    Seattle, Washington, 98122

  • Investigational Drug Service Pharmacy, Swedish Medical Center.

    Seattle, Washington, 98122

  • Seattle Rheumatology Associates

    Seattle, Washington, 98122

  • Swedish Medical Center

    Seattle, Washington, 98122

  • Clinical Pharmacology Study Group

    Worcester, Massachusetts, 01605

Other trials in United States

Poland17 sites
  • Niepubliczny Zaklad Opieki Zdrowotnej Przychodnia Chirurgiczna dla Dzieci "PriamaMed" Sp.P.,"

    Bialystok, 15-002

  • ZDROWIE OSTEO-MEDIC s.c. L. i A. Racewicz, A. i J. Supronik

    Bialystok, 15-351

  • ClinicMed Badurski i wspolnicy Spolka Jawna

    Bialystok, 15-879

  • Szpital Uniwersytecki nr 2 im. dr Jana Biziela w Bydgoszczy,

    Bydgoszcz, 85-168

  • Centrum Kliniczno-Badawcze J.Brzezicki, B.Gornikiewicz-Brzezicka Lekarze Spolka Partnerska

    Elblag, 82-300

  • Centrum Radiologii for X-Ray only

    Elblag, 82-300

  • NZOZ Centrum Reumatologiczne Indywidualna Specjalistyczna Praktyka Lekarska Lek. Med. Barbara Bazela

    Elblag, 82-300

  • Przychodnia Specjalistyczna Lekarskiej Spoldzielni Pracy "Medica"

    Grodzisk Mazowiecki, 05-825

  • Zespol Poradni Specjalistycznych Reumed Filia Onyksowa

    Lublin, 20-582

  • NZOZ Lecznica MAK-MED S.C.

    Nadarzyn, 05-830

  • Prywatna Praktyka Lekarska Prof. UM dr hab. Pawel Hrycaj

    Poznan, 61-397

  • NZOZ Nasz Lekarz Praktyka Grupowa Lekarzy Rodzinnych z Przychodnia Specjalistyczna w Toruniu

    Torun, 87-100

  • Medica Pro Familia Sp. z o.o. S.K.A.

    Warsaw, 01-868

  • Rheuma Medicus Zaklad Opieki Zdrowotnej

    Warsaw, 02-118

  • Reumatika Centrum Reumatologii

    Warsaw, 02-691

  • Klinika Ambroziak Estederm Sp. z o.o. ,S.K.A

    Warsaw, 02-758

  • Synexus Polska Sp. z o.o. Oddz. we Wroclawiu

    Wroclaw, 50-088

Other trials in Poland

Czechia13 sites
  • Revmacentrum MUDr. Mostera, s.r.o.

    Brno, Czech Republic, 615 00

  • Lekarna Na Lidicke (Pharmacy only)

    Brno, 602 00

  • X-MEDICA s.r.o (radiology only)

    Brno, 61300

  • Revmatologie s.r.o.

    Brno, 638 00

  • Stavovska s.r.o. (pharmacy only)

    Brno, 63800

  • Vesalion s.r.o.

    Ostrava, 70200

  • Revmatologicky Ustav - Lekarna (pharmacy only)

    Prague, Czech Republic, 128 50

  • Revmatologicka ambulance

    Prague, Czech Republic, 140 00

  • Revmatologicky ustav - Lekarna

    Prague, 128 50

  • Revmatologicky ustav

    Prague, 128 50

  • MEDIGAP, s.r.o. (radiology only)

    Praha 1 - Nove Mesto, Czech Republic, 110 00

  • MEDIGAP, s.r.o

    Praha 1- Nove Mesto, 110 00

  • Medical Plus s.r.o. Lekarna Hradebni s. r.o

    Uherské Hradiště, 68601

Other trials in Czechia

Mexico13 sites
  • Investigacion y Biomedicina de Chihuahua SC

    Chihuahua City, 31000

  • Centro de Investigacion de Tratamientos Innovadores de Sinaloa, S.C.

    Culiacán, Sinaloa, 80000

  • Laboratorios de Analisis Clinicos CEMSI

    Culiacán, Sinaloa, 80000

  • Sanatorio CEMSI Chapultepec (For Emergencies Only)

    Culiacán, Sinaloa, 80040

  • Hospital General de Culiacán Dr. Bernardo J. Gastélum

    Culiacán, Sinaloa, 80230

  • Centro Integral en Reumatologia SA de CV

    Guadalajara, Jalisco, 44160

  • Instituto Medico Panamericano, S.A. de C.V. (For Emergencies Only)

    Mérida, Yucatán, 97000

  • Unidad Reumatologica Las Americas, S.C.P.

    Mérida, Yucatán, 97000

  • Centro de Investigacion Clinica Pensiones

    Mérida, Yucatán, 97070

  • Centro Multidisciplinario para el Desarrollo Especializado de la Investigacion Clinica en Yucatan

    Mérida, Yucatán, 97130

  • Hospital Star Medica Merida (For Emergencies Only)

    Mérida, Yucatán, 97133

  • HOSPITAL STAR MEDICA S.A DE C.V- (emergencies only)

    Mérida, Yucatán, 97133

  • Cliditer, S. A. de C. V

    Mexico City, 06700

Other trials in Mexico

Russia8 sites
  • State Budgetary Institution of Healthcare of Moscow City Clinical Hospital

    Moscow, 119049

  • OOO City Neurological Centre "Sibneiromed"

    Novosibirsk, 630091

  • Limited Liability Company Consultative Diagnostic Rheumatology Center "Healthy Joints"

    Novosibirsk, 630099

  • Regional State Budgetary Healthcare Institution of Karelia Republic

    Petrozavodsk, Karelia Republic, 185019

  • State Institution of Healthcare "Regional Clinical Hospital"

    Saratov, 410053

  • State Budget Educational Institution of Highest Professional Education

    Tomsk, 634050

  • State Healthcare Institution of Yaroslavl Region Clinical Emergency Hospital n.a. N.V. Solovyev

    Yaroslavl, 150003

  • State Institution of Healthcare of Yaroslavl Region

    Yaroslavl, 150003

Other trials in Russia

United Kingdom7 sites
  • Bradford Teaching Hospitals NHS Foundation Trust

    Bradford, West Yorkshire, BD5 0NA

  • Bradford Royal Infirmary, BTHFT

    Bradford, West Yorkshire, BD9 6RJ

  • The Dudley Group NHS Foundation Trust

    Dudley, West Midlands, DY1 2HQ

  • Barking Havering and Redbridge University Hospital NHS Trust-King George Hospital

    Goodmayes, Essex, IG3 8YB

  • Barking, Havering and Redbridge University Hospitals NHS Trust

    Romford, Essex, RM7 0AG

  • Wirral University Teaching Hospital NHS Foundation Trust

    Upton, Wirral, CH49 5PE

  • York Teaching Hospital NHS Foundation Trust

    York, YO31 8HE

Other trials in United Kingdom

Australia6 sites
  • Monash Health, Monash Medical Centre

    Clayton, Victoria, 3168

  • Pharmacy Clinical Trials

    Clayton, Victoria, 3168

  • St. Vincent's Hospital (Melbourne)

    Fitzroy, Victoria, 3065

  • Emeritus Research Pty Ltd

    Malvern East, Victoria, 3145

  • Rheumatology Research Unit

    Maroochydore, Queensland, 4558

  • Pacific Private Clinic

    Southport, Queensland, 4215

Other trials in Australia

Spain6 sites
  • Complexo Hospitalario Universitario A Coruna

    A Coruña, 15006

  • Corporació Sanitaria Parc Tauli

    Sabadell, Barcelona, 08208

  • Hospital Universitario Marques de Valdecilla

    Santander, Cantabria, 39008

  • Hospital Clinico de Santiago

    Santiago de Compostela, A Coruna, 15706

  • Hospital Infanta Luisa

    Seville, 41010

  • Hospital Universitario y Politecnico La Fe

    Valencia, 46026

Other trials in Spain

Bulgaria5 sites
  • UMHAT "Dr. G. Stranski" EAD

    Pleven, 5800

  • MHAT"Plovdiv" AD

    Plovdiv, 4000

  • MHAT "Kaspela" EOOD

    Plovdiv, 4002

  • UMHAT "Sv. Ivan Rilski" EAD

    Sofia, 1612

  • MC "New rehabilitation center" EOOD, Rheumatology Cabinet

    Stara Zagora, 6003

Other trials in Bulgaria

Germany5 sites
  • Charite Universitaetsmedizin Berlin

    Berlin, 10117

  • Klinische Forschung Berlin-Mitte GmbH

    Berlin, 10117

  • Rheumapraxis Steglitz

    Berlin, 12161

  • University Hospital of Cologne

    Cologne, 50937

  • Klinische Forschung Schwerin GmbH

    Schwerin, 19055

Other trials in Germany

Hungary5 sites
  • Revita Reumatologiai Rendelo

    Budapest, 1027

  • Qualiclinic Kft.

    Budapest, 1036

  • Magyar Honvedseg Egeszsegugyi Kozpont,Reumatologiai osztaly

    Budapest, 1062

  • Csolnoky Ferenc Korhaz, Radiologiai Osztaly X-Ray Only

    Veszprém, 8200

  • Csolnoky Ferenc Korhaz, Reumatologiai Osztaly

    Veszprém, 8200

Other trials in Hungary

Slovakia4 sites
  • ROMJAN s.r.o., Reumatologicka ambulancia

    Bratislava, Slovak Republic, 832 63

  • Nestatna reumatologicka ambulancia

    Bratislava, 841 04

  • MEDMAN s.r.o. - reumatologicka ambulancia

    Martin, Slovak Republic, 036 01

  • Reumex s.r.o

    Rimavská Sobota, 979 01

Other trials in Slovakia

Taiwan4 sites
  • Buddhist Dalin Tzu Chi General Hospital

    Chiayi City, 62247

  • Chang Gung Medical Foundation-Kaohsiung Branch

    Kaohsiung City, 83301

  • Chung Shan Medical University Hospital

    Taichung, 40201

  • Taipei Veterans General Hospital

    Taipei, Taiwan Roc, 11217

Other trials in Taiwan

Canada3 sites
  • Rheumatology Research Associates

    Edmonton, Alberta, T5M 0H4

  • West Island Rheumatology Research Associates

    Pointe-Claire, Quebec, H9R 3J1

  • K. Papp Clinical Research

    Waterloo, Ontario, N2J 1C4

Other trials in Canada

Belgium2 sites
  • Hopital Erasme - Clinique Universitaire de Bruxelles

    Brussels, 1070

  • University Hospital Leuven, Department of Rheumatology

    Leuven, 3000

Other trials in Belgium

France1 site
  • Centre Hospitalier Sud-Francilien - Secretariat de Rhumatologie

    Corbeil-Essonnes, 91106

Other trials in France

About this study

Official title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis

This is a 12-month study investigating the effectiveness and safety of tofactinib in treating the signs and symptoms of active psoriatic arthritis and improving physical function and preserving bone structure in patients with an inadequate response to a traditional, nonbiologic disease-modifying antirheumatic drug. Adalimumab is used as a comparator.

Being tested
Tofacitinib 5 mg BID, Tofacitinib 10 mg BID, Adalimumab, Placebo
Keywords
psoriatic arthritis, radiographic changes, active comparator, tofacitinib
Medical subject headings
Arthritis, Psoriatic

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Tofacitinib 5 mg BIDDrug

    Tofacitinib orally (po) 1 tablet of 5 mg and placebo po 1 tablet BID x 12 months Placebo injections subcu every 2 weeks x 12 months

  • Tofacitinib 10 mg BIDDrug

    Tofacitinib po 2 tablets of 5 mg BID x 12 months Placebo injections subcu every 2 weeks x 12 months

  • AdalimumabDrug

    Placebo po 2 tablets BIDx 12 months Adalimumab 40 mg subcu injections every 2 weeks x 12 months

  • PlaceboDrug

    Placebo po 2 tablets BIDx 3 months followed by tofacitinib po 1 tablet of 5 mg and placebo po 1 tablet BID x 9 months Placebo injections every 2 weeks x 12 months

  • PlaceboDrug

    Placebo po 2 tablets BIDx 3 months followed by tofacitinib po 2 tablets (5 mg) BID x 9 months Placebo injections every 2 weeks x 12 months

Study groups in NCT01877668
Study groupRoleWhat they receive
Tofacitinib 5 mgBID x 12 monthsExperimentalNot described
Receives: Drug: Tofacitinib 5 mg BID
Tofacitinib 10 mg BID x 12 monthsExperimentalNot described
Receives: Drug: Tofacitinib 10 mg BID
Adalimumab 40 mg q2 weeks x 12 monthsActive comparatorNot described
Receives: Drug: Adalimumab
Placebo x3 months, then tofacitinib 5 mg BIDx 9 monthsPlacebo comparatorNot described
Receives: Drug: Placebo
Placebo x 3 months, then tofacitinib 10 mg BID x 9 monthsPlacebo comparatorNot described
Receives: Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥20% (ACR20): Month 3

    ACR20 was calculated as a ≥20% improvement from baseline in tender/painful and swollen joint counts and ≥20% improvement from baseline in 3 of the 5 remaining ACR core set measures: patient's global assessment of arthritis, physician's global assessment of arthritis, patient's assessment of arthritis pain, health assessment questionnaire - disability index (HAQ-DI), and C-reactive protein (CRP).

    Measured: At end of Month 3

  2. Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score

    The HAQ-DI assesses the difficulty a participant has had in the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2-3 items. For each question, level of difficulty is scored from 0 to 3 with 0=no difficulty, 1=some difficulty, 2=much difficulty, and 3=unable to do. The score for each domain is the maximum (worst) score from the items/questions within the domain. Higher score indicates greater disability.

    Measured: From Baseline to Month 3

Secondary outcomes (38)
  1. Change From Baseline in the Van Der Heijdel Modified Total Sharp Score (mTSS) for Psoriatic Arthritis

    Assessment of joint damage includes a joint erosion score (range 0-320) and a joint space narrowing (JSN) score (range 0-208). The mTSS is the sum of the erosion and JSN scores (range 0-528). A higher score indicates more severe disease status. If a component score is missing, the mTSS will be missing.

    Measured: From Baseline to Month 12

  2. Percentage of Participants With Progressed Modified Total Sharp Score (mTSS) at Month 12

    Assessment of joint damage includes a joint erosion score (range 0-320) and a JSN score (range 0-208). The mTSS is the sum of the erosion and JSN scores (range 0-528). A higher score indicates more severe disease status. If a component score is missing, the mTSS will be missing. Progressor is defined as an increase in mTSS >0.5 from baseline.

    Measured: At Month 12

  3. Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥50% (ACR50) at Week 2 and Months 1, 2, 3, 4, 6, 9, and 12

    ACR50 was calculated as a ≥50% improvement from baseline in tender/painful and swollen joint counts and ≥50% improvement from baseline in 3 of the 5 remaining ACR core set measures: patient's global assessment of arthritis, physician's global assessment of arthritis, patient's assessment of arthritis pain, HAQ-DI, and CRP.

    Measured: At Week 2 and Months 1, 2, 3, 4, 6, 9, and 12

  4. Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥70% (ACR70) at Week 2 and Months 1, 2, 3, 4, 6, 9, and 12

    ACR70 was calculated as a ≥70% improvement from baseline in tender/painful and swollen joint counts and ≥70% improvement from baseline in 3 of the 5 remaining ACR core set measures: patient's global assessment of arthritis, physician's global assessment of arthritis, patient's assessment of arthritis pain, HAQ-DI, and CRP.

    .

    Measured: At Week 2 and Months 1, 2, 3, 4, 6, 9, and 12

  5. Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥20% (ACR20) at Week 2 and Months 1, 2, 4, 6, 9, and 12

    ACR20 was calculated as a ≥20% improvement from baseline in tender/painful and swollen joint counts and ≥20% improvement from baseline in 3 of the 5 remaining ACR core set measures: patient's global assessment of arthritis, physician's global assessment of arthritis, patient's assessment of arthritis pain, HAQ-DI, and CRP.

    Measured: At Week 2 and Months 1, 2, 4, 6, 9, and 12

  6. Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score

    The HAQ-DI assesses the difficulty a participant has had in the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2-3 items. For each question, level of difficulty is scored from 0 to 3 with 0=no difficulty, 1=some difficulty, 2=much difficulty, and 3=unable to do. The score for each domain is the maximum (worst) score from the items/questions within the domain. Higher score indicates greater disability.

    Measured: From Baseline to Week 2 and Months 1, 2, 4, 6, 9, and 12

  7. Change From Baseline in American College of Rheumatology Response Criteria Components: C-reactive Protein Levels

    The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.

    Measured: From Baseline to end of Month 3

  8. Change From Baseline in American College of Rheumatology Response Criteria Components Score: Patient's Assessment of Arthritis Pain

    Participants assessed the severity of their arthritis pain using a 100-mm visual analog scale (VAS) by placing a mark on the scale between 0 (no pain) and 100 (most severe pain), which corresponded to the magnitude of their pain.

    Measured: From Baseline to end of Month 3

  9. Change From Baseline in American College of Rheumatology Response Criteria Components Score: Patient's Global Assessment of Arthritis

    Participant answered the following question, "Considering all the ways your arthritis affects you, how are you feeling today?" The participant's response was recorded using a 100 mm VAS by placing a mark on the scale between 0 (very well) and 100 (very poorly).

    Measured: From Baseline to end of Month 3

  10. Change From Baseline in American College of Rheumatology Response Criteria Components Score: Physician's Global Assessment of Arthritis

    The blinded investigator or qualified assessor assessed how the participant's overall arthritis appeared at the time of the visit. This was an evaluation based on the participant's disease signs, functional capacity and physical examination, and was independent of the Patient's Global Assessment of Arthritis. The investigator's response was recorded using a 100 mm VAS by placing a mark on the scale between 0 (very good) and 100 (very poor).

    Measured: From Baseline to end of Month 3

  11. Change From Baseline in American College of Rheumatology Response Criteria Components Score: Swollen Joint Count

    Swollen joint counts are considered the most specific quantitative clinical measure used to assess the status of participants with inflammatory types of arthritis. Sixty six (66) joints were assessed by a blinded assessor to determine the number of joints that were considered swelling.

    Measured: From Baseline to end of Month 3

  12. Change From Baseline in American College of Rheumatology Response Criteria Components Score: Tender/Painful Joint Count

    Tender/painful joint counts are considered the most specific quantitative clinical measure used to assess the status of participants with inflammatory types of arthritis. Sixty eight (68) joints were assessed by a blinded assessor to determine the number of joints that were considered tender or painful.

    Measured: From Baseline to end of Month 3

  13. Percentage of Participants Meeting Psoriatic Arthritis Response Criteria (PsARC) at Week 2 and Months 1, 2, 3, 4, 6, 9, and 12

    The PsARC covers 4 measures: Tender/painful joint count, swollen joint count, the Physician's Global Assessment of Arthritis, and the Patient's Global Assessment of Arthritis. The PsARC response is defined as improvement in 2 of 4 items, 1 of which must be joint pain or swelling, without worsening in any measure. Improvement criteria: ≥20% improvement in Physician's Global Assessment of Arthritis; ≥20% improvement in Patient's Global Assessment of Arthritis; ≥30% improvement in tender joint count; and ≥30% improvement in swollen joint count.

    Measured: At Week 2 and Months 1, 2, 3, 4, 6, 9, and 12

  14. Change From Baseline in Physician's Global Assessment of Psoriasis (PGA-PsO) Response

    The PGA-PsO is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are rated separately over the whole body according to a 5-point severity scale, scored as 0=none; 1, 2, 3, or 4=most severe. The severity rating scores are summed and the average taken; the total average is rounded to the nearest whole number score to determine a PGA-PsO score on a scale of 0 to 4 (0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe).

    Measured: From Baseline to Months 1, 3, 6, 9, and 12

  15. Percentage of Participants With Psoriasis Area and Severity Index 75 (PASI75) Response at Months 1, 3, 6, 9, and 12

    PASI determines psoriasis severity based on lesion severity \& percentage body surface area (BSA) affected. Lesion severity is assessed for erythema, induration, \& scaling, evaluated separately for head \& neck, upper limbs, trunk, \& lower limbs \& rated for each body area according to a 5 point scale: 0=no involvement; 1=slight; 2=moderate; 3=marked; 4=very marked. BSA involvement is the extent (%) of body area affected by psoriasis \& is assigned a score: 0=no involvement; 1=0-9%; 2=10-29%; 3=30-49%; 4=50-69%; 5=70-89%; 6=90-100%. In each area, sum of severity rating scores is multiplied by the score representing the percentage of area involved by psoriasis, multiplied by a weighting factor (head 0.1; upper limbs 0.2; trunk 0.3; lower limbs 0.4). The sum of numbers obtained for the 4 body areas is the PASI score \& can vary in increments of 0.1 \& range from 0.0 to 72.0, higher scores represent greater severity of psoriasis. PASI75 is defined as a 75% reduction from baseline in PASI.

    Measured: At Months 1, 3, 6, 9, and 12

  16. Change From Baseline in Dactylitis Severity Score (DSS)

    Dactylitis is characterized by swelling of the entire finger or toe. The DSS is a function of finger circumference and tenderness, assessed and summed across all dactylitic digits. The severity of dactylitis is scored on a scale of 0-3, where 0=no tenderness and 3=extreme tenderness in each digit of the hands and feet. The range of total dactylitis scores for a patient is 0-60. Higher score indicates greater degree of tenderness.

    Measured: From Baseline to Months 1, 3, 6, 9, and 12

  17. Change From Baseline in the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index

    The SPARCC Enthesitis Index identifies the presence or absence of tenderness at 16 enthesial sites, including the bilateral Achilles tendons, plantar fascia insertion at the calcaneus, patellar tendon insertion at the base of the patella, quadriceps insertion into the superior border of the patella, supraspinatus insertion into the greater tuberosity of the humerus, and medial and lateral epicondyles. On examination, tenderness is recorded as present (1) or absent (0) for each of the 16 sites, with an overall total score ranging from 0 to 16. Higher score indicates a greater number of sites that are affected by enthesitis.

    Measured: From Baseline to Months 1, 3, 6, 9, and 12

  18. Change From Baseline in the Leeds Enthesitis Index (LEI)

    Enthesitis is inflammation in the tendon, ligament, and joint capsule fiber insertion into bone. The LEI assesses enthesitis in 6 sites. Tenderness is recorded as either present (1) or absent (0) for each of the 6 sites, for an total score of 0-6. Higher score indicates a greater number of sites that are affected by enthesitis.

    Measured: From Baseline to Months 1, 3, 6, 9, and 12

  19. Change From Baseline in the Short-Form-36 Health Survey Version 2 (SF-36v2) Acute, Physical Component Summary Score

    The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. An additional item measures health transition. The 8 health domains are aggregated into two summary scores known as the physical component summary (PCS) score and the mental component summary (MCS) score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a standard deviation (SD) of 10 points, and ranges from minus infinity to plus infinity. A higher PCS score represents better physical health status.

    Measured: From Baseline to Months 1, 3, 6, 9, and 12

  20. Change From Baseline in the Short-Form-36 Health Survey Version 2 (SF-36v2), Acute, Mental Component Summary Score

    The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. An additional item measures health transition. The 8 health domains are aggregated into two summary scores known as the PCS score and the MCS score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher MCS score represents better mental health status.

    Measured: From Baseline to Months 1, 3, 6, 9, and 12

  21. Change From Baseline in the Short-Form-36 Health Survey Version 2 (SF-36v2), Acute Components: Physical Functioning Domain

    The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. An additional item measures health transition. The 8 health domains are aggregated into two summary scores known as the PCS score and the MCS score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher physical functioning domain score represents better physical functioning.

    Measured: From Baseline to Months 1, 3, 6, 9, and 12

  22. Change From Baseline in the Short-Form-36 Health Survey Version 2 (SF-36v2), Acute Components: Role-Physical Domain

    The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. An additional item measures health transition. The 8 health domains are aggregated into two summary scores known as the PCS score and the MCS score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher role-physical domain score represents better role-physical functioning.

    Measured: From Baseline to Months 1, 3, 6, 9, and 12

  23. Change From Baseline in the Short-Form-36 Health Survey Version 2 (SF-36v2), Acute Components: Bodily Pain Domain

    The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. An additional item measures health transition. The 8 health domains are aggregated into two summary scores known as the PCS score and the MCS score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher bodily pain domain score represents less bodily pain.

    Measured: From Baseline to Months 1, 3, 6, 9, and 12

  24. Change From Baseline in the Short-Form-36 Health Survey Version 2 (SF-36v2), Acute Components: General Health Domain

    The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. An additional item measures health transition. The 8 health domains are aggregated into two summary scores known as the PCS score and the MCS score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher general health domain score represents better general health perceptions.

    Measured: From Baseline to Months 1, 3, 6, 9, and 12

  25. Change From Baseline in the Short-Form-36 Health Survey Version 2 (SF-36v2), Acute Components: Vitality Domain

    The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. An additional item measures health transition. The 8 health domains are aggregated into two summary scores known as the PCS score and the MCS score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher vitality domain score represents better vitality.

    Measured: From Baseline to Months 1, 3, 6, 9, and 12

  26. Change From Baseline in the Short-Form-36 Health Survey Version 2 (SF-36v2), Acute Components: Social Functioning Domain

    The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. An additional item measures health transition. The 8 health domains are aggregated into two summary scores known as the PCS score and the MCS score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher social functioning domain score represents better social functioning.

    Measured: From Baseline to Months 1, 3, 6, 9, and 12

  27. Change From Baseline in the Short-Form-36 Health Survey Version 2 (SF-36v2), Acute Components: Role-Emotional Domain

    The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. An additional item measures health transition. The 8 health domains are aggregated into two summary scores known as the PCS score and the MCS score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher role-emotional domain score represents better role-emotional functioning.

    Measured: From Baseline to Months 1, 3, 6, 9, and 12

  28. Change From Baseline in the Short-Form-36 Health Survey Version 2 (SF-36v2), Acute Components: Mental Health Domain

    The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. An additional item measures health transition. The 8 health domains are aggregated into two summary scores known as the PCS score and the MCS score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher mental health domain score represents better mental health functioning.

    Measured: From Baseline to Months 1, 3, 6, 9, and 12

  29. Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Mobility

    The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems [1], some or moderate problems [2], or extreme problems [3]) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm visual analogue scale (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state, with a higher value representing better health status.

    Measured: From Baseline to Months 1, 3, 6, 9, and 12

  30. Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Self-care

    The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems [1], some or moderate problems [2], or extreme problems [3]) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm visual analogue scale (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state, with a higher value representing better health status.

    Measured: From Baseline to Months 1, 3, 6, 9, and 12

  31. Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Usual Activities

    The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems [1], some or moderate problems [2], or extreme problems [3]) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm visual analogue scale (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state, with a higher value representing better health status.

    Measured: From Baseline to Months 1, 3, 6, 9, and 12

  32. Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Pain/Discomfort

    The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems [1], some or moderate problems [2], or extreme problems [3]) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm visual analogue scale (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state, with a higher value representing better health status.

    Measured: From Baseline to Months 1, 3, 6, 9, and 12

  33. Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Anxiety/Depression

    The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems [1], some or moderate problems [2], or extreme problems [3]) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm visual analogue scale (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state, with a higher value representing better health status.

    Measured: From Baseline to Months 1, 3, 6, 9, and 12

  34. Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Patient's Health State Today

    The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems [1], some or moderate problems [2], or extreme problems [3]) within a particular EQ-5D dimension. Standard vertical 0 (worst imaginable health state) to 100 mm (best imaginable health state) visual analogue scale (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state; higher scores indicate a better health state, with a higher value representing better health status.

    Measured: From Baseline to Months 1, 3, 6, 9, and 12

  35. Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Total Score

    FACIT-F is a 13-item questionnaire, with each item scored on a 5-point scale ranging from 0 (not at all) to 4 (very much). Three endpoints are derived: change in FACIT-F total score, change in FACIT-F experience domain score, and change in FACIT-F impact domain score. FACIT-F total score (range 0 to 52) is calculated by summing the 13 items. FACIT-F experience domain score (range 0-20) is calculated by summing 5 items : I feel fatigued, I feel weak all over, I feel listless ("washed out"), I feel tired, and I have energy, while FACIT-F impact domain score (range 0-32) is calculated by summing the remaining 8 items. All responses are added with equal weight to obtain the total score. Higher scores represent better fatigue status.

    Measured: From Baseline to Months 1, 3, 6, 9, and 12

  36. Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Experience Domain Score

    FACIT-F is a 13-item questionnaire, with each item score ranging from 0 to 4. Three endpoints are derived: change in FACIT-F total score, change in FACIT-F experience domain score, and change in FACIT-F impact domain score. FACIT-F total score (range 0-52) is calculated by summing the 13 items. FACIT-F experience domain score (range 0-20) is calculated by summing 5 items : I feel fatigued, I feel weak all over, I feel listless ("washed out"), I feel tired, and I have energy, while FACIT-F impact domain score (range 0-32) is calculated by summing the remaining 8 items. All responses are added with equal weight to obtain the total score. Higher scores represent better (less) fatigue experience.

    Measured: From Baseline to Months 1, 3, 6, 9, and 12

  37. Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Impact Domain Score

    FACIT-F is a 13-item questionnaire, with each item score ranging from 0 to 4. Three endpoints are derived: change in FACIT-F total score, change in FACIT-F experience domain score, and change in FACIT-F impact domain score. FACIT-F total score (range 0-52) is calculated by summing the 13 items. FACIT-F experience domain score (range 0-20) is calculated by summing 5 items : I feel fatigued, I feel weak all over, I feel listless ("washed out"), I feel tired, and I have energy, while FACIT-F impact domain score (range 0-32) is calculated by summing the remaining 8 items. All responses are added with equal weight to obtain the total score. Higher scores represent better (less) fatigue impact on daily functioning.

    Measured: From Baseline to Months 1, 3, 6, 9, and 12

  38. Change From Baseline in Scores Evaluating Spondylitis Using the Bath Anklyosing Spondylitis Disease Activity Index (BASDAI)

    BASDAI is a validated self-assessment tool used to determine disease activity in participants with ankylosing spondylitis. Utilizing a visual analog scale of 0-100mm (0=none and 100=very severe) participants answer 6 questions measuring discomfort, pain, and fatigue. The final BASDAI score averages the individual assessments for a final score ranging 0-10cm, with higher scores representing more severe ankylosing spondylitis disease activity.

    Measured: From Baseline to Months 1, 3, 6, 9, and 12

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Jun 2013 (estimated)
  2. Study start20 Jan 2014
  3. Primary completion18 Dec 2015
  4. Study completion18 Dec 2015

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
422 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01877668
Sponsor's protocol ID
A3921091
Other IDs
2011-003668-55
Acronym
OPAL BROADEN
Status last verified
Jun 2017
First submitted
12 Jun 2013
Last updated
6 Jul 2017
Data monitoring committee
Yes
Individual data sharing
Yes: Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical\_trials/trial\_data\_and\_results/data\_requests

Publications

  • Gossec L, Sellas A, Gruben DC, Valderrama M, Gomez S, Kinch C, Citera G. Response to Tofacitinib in Patients with Psoriatic Arthritis and Probable Anxiety/Depressive Disorder: A Post Hoc Analysis of Phase 3 Trials. Rheumatol Ther. 2025 Dec;12(6):1175-1186. doi: 10.1007/s40744-025-00800-7. Epub 2025 Oct 28.

    PubMed 41148555
  • Gladman D, Tillett W, Gruben D, Coates LC, Hahne S, Volkov M. Identification of distinct disease activity trajectories in patients with psoriatic arthritis receiving tofacitinib: a post hoc analysis of two phase 3 studies. RMD Open. 2025 Jun 3;11(2):e005250. doi: 10.1136/rmdopen-2024-005250.

    PubMed 40461265
  • Gladman DD, Dougados M, Marzo-Ortega H, Cadatal MJ, Agarwal E, Kinch CD, Nash P. Long-term tofacitinib efficacy and safety in psoriatic arthritis with or without prior biologic DMARD exposure: a post hoc analysis. Rheumatol Adv Pract. 2025 Jan 21;9(2):rkaf008. doi: 10.1093/rap/rkaf008. eCollection 2025.

    PubMed 40241921
  • Gladman DD, Nash P, Mease PJ, FitzGerald O, Duench S, Cadatal MJ, Masri KR. Efficacy and safety of tofacitinib in an open-label, long-term extension study in patients with psoriatic arthritis who received adalimumab or tofacitinib in a Phase 3 randomized controlled study: a post hoc analysis. Arthritis Res Ther. 2024 Dec 19;26(1):218. doi: 10.1186/s13075-024-03442-2.

    PubMed 39702318
  • Menon S, Shoji S, Tsuchiwata S, Fallon L, Kanik K. Exposure-Response Analysis of Tofacitinib in Active Psoriatic Arthritis: Results from Two Phase 3 Studies. J Clin Pharmacol. 2025 Mar;65(3):369-377. doi: 10.1002/jcph.6147. Epub 2024 Oct 25.

    PubMed 39453735
  • Mease PJ, Orbai AM, FitzGerald O, Bedaiwi M, Dona L Fleishaker, Mundayat R, Young P, Helliwell PS. Efficacy of tofacitinib on enthesitis in patients with active psoriatic arthritis: analysis of pooled data from two phase 3 studies. Arthritis Res Ther. 2023 Aug 22;25(1):153. doi: 10.1186/s13075-023-03108-5.

    PubMed 37608391
  • Eder L, Gladman DD, Mease P, Pollock RA, Luna R, Aydin SZ, Ogdie A, Polachek A, Gruben D, Cadatal MJ, Kinch C, Strand V. Sex differences in the efficacy, safety and persistence of patients with psoriatic arthritis treated with tofacitinib: a post-hoc analysis of phase 3 trials and long-term extension. RMD Open. 2023 Mar;9(1):e002718. doi: 10.1136/rmdopen-2022-002718.

    PubMed 36958766
  • Kristensen LE, Danese S, Yndestad A, Wang C, Nagy E, Modesto I, Rivas J, Benda B. Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance. Ann Rheum Dis. 2023 Jul;82(7):901-910. doi: 10.1136/ard-2022-223715. Epub 2023 Mar 17.

    PubMed 36931693
  • Dougados M, Taylor PC, Bingham CO 3rd, Fallon L, Brault Y, Roychoudhury S, Wang L, Kessouri M. The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis. RMD Open. 2022 Sep;8(2):e002478. doi: 10.1136/rmdopen-2022-002478.

    PubMed 36814062
  • Winthrop KL, Yndestad A, Henrohn D, Danese S, Marsal S, Galindo M, Woolcott JC, Jo H, Kwok K, Shapiro AB, Jones TV, Diehl A, Su C, Panes J, Cohen SB. Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs. Rheumatol Ther. 2023 Apr;10(2):357-373. doi: 10.1007/s40744-022-00507-z. Epub 2022 Dec 17.

    PubMed 36526796
  • Schneeberger EE, Citera G, Nash P, Smolen JS, Mease PJ, Soriano ER, Helling C, Szumski AE, Mundayat R, de Leon DP. Comparison of disease activity index for psoriatic arthritis (DAPSA) and minimal disease activity (MDA) targets for patients with psoriatic arthritis: A post hoc analysis of data from phase 3 tofacitinib studies. Semin Arthritis Rheum. 2023 Feb;58:152134. doi: 10.1016/j.semarthrit.2022.152134. Epub 2022 Nov 13.

    PubMed 36476498
  • de Vlam K, Mease PJ, Bushmakin AG, Fleischmann R, Ogdie A, Azevedo VF, Merola JF, Woolcott J, Cappelleri JC, Fallon L, Taylor PC. Identifying and Quantifying the Role of Inflammation in Pain Reduction for Patients With Psoriatic Arthritis Treated With Tofacitinib: A Mediation Analysis. Rheumatol Ther. 2022 Oct;9(5):1451-1464. doi: 10.1007/s40744-022-00482-5. Epub 2022 Sep 8.

    PubMed 36076054
  • Orbai AM, Mease PJ, Helliwell PS, FitzGerald O, Fleishaker DL, Mundayat R, Young P. Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: post-hoc analysis of phase III studies. BMC Rheumatol. 2022 Sep 1;6(1):68. doi: 10.1186/s41927-022-00298-4.

    PubMed 36045453
  • Taylor PC, Bushmakin AG, Cappelleri JC, Young P, Germino R, Merola JF, Yosipovitch G. Relationships of dermatologic symptoms and quality of life in patients with psoriatic arthritis: analysis of two tofacitinib phase III studies. J Dermatolog Treat. 2022 Aug;33(5):2614-2620. doi: 10.1080/09546634.2022.2060924. Epub 2022 Apr 11.

    PubMed 35385361
  • Gladman DD, Coates LC, Wu J, Fallon L, Bacci ED, Cappelleri JC, Bushmakin AG, Helliwell PS. Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo. Arthritis Res Ther. 2022 Feb 9;24(1):40. doi: 10.1186/s13075-022-02721-0.

    PubMed 35139908

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Tofacitinib 5 mg BID, Tofacitinib 10 mg BID and Adalimumab in people with Psoriatic Arthritis, run by Pfizer at 123 sites in 16 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 6 Jul 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 123 sites in United States, Poland, Czechia, Mexico, Russia and 11 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 6 Jul 2017). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥20% (ACR20): Month 3 (time frame: At end of Month 3). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01877668, which also lists 31 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Jul 2017.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in